^
Association details:
| Biomarker: | BCOR mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | azacitidine (DNA methylation inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Published date:
05/18/2021
Excerpt:
...newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group)…mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS).
DOI:
10.3390/cancers13102458
Trial ID:
